SARSYS (SARS) Q2 2024 earnings summary

Executive summary

• Revenue declined 32% in Q2 2024 to 8.3 MSEK and 16% for H1 2024 to 16.2 MSEK compared to prior year periods.

• Operating loss deepened to -4.9 MSEK in Q2 and -7.9 MSEK for H1 2024, reflecting continued market challenges.

• Order intake for H1 2024 rose to 24.9 MSEK, surpassing full-year 2023, driven by a major Cerema order.

• Financial position weakened, with equity ratio at 2% and equity per share at 0.06 SEK.

• Management prioritizes improving liquidity and equity, with further capital injections possible.

Financial highlights

• Q2 2024 net sales: 8.3 MSEK (12.2 MSEK Q2 2023); H1 2024: 16.2 MSEK (19.4 MSEK H1 2023).

• Q2 2024 operating result: -4.9 MSEK (-1.4 MSEK Q2 2023); H1 2024: -7.9 MSEK (-1.4 MSEK H1 2023).

• EPS: -0.37 SEK in Q2 2024 (-0.14 SEK Q2 2023); -0.60 SEK for H1 2024 (-0.17 SEK H1 2023).

• Gross margin for H1 2024: 55% (58% H1 2023).

• Cash flow from operations for H1 2024: -1.6 MSEK (4 MSEK H1 2023); total cash flow positive at 2.9 MSEK due to new share issue.

Outlook and guidance

• Management expresses cautious optimism for Q3 2024, focusing on operational efficiency and financial discipline.

• Further capital injections may be required to ensure long-term sustainability.